Clinical trials: Chemotherapy
Inflammatory Bowel Diseases, Colitis, Ulcerative
Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
The purpose of this study is to determine if a relationship exists between Week 6 vedolizumab therapeutic drug monitoring (TDM) and Week 30 Faecal calprotectin (FCP).
- Conditions
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
- Trial name
- VEDO TDM RWE (NCT04567628)
- Testing
- No Intervention
- Where
- Canada
- Volunteers
- 7,873 people
- Sponsor
- Takeda
Esophageal Cancer, Gastric Cancer
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
The purpose of this study is to find out what effects, good and/or bad, pembrolizumab in combination with trastuzumab and chemotherapy, has on the patients' esophagogastric cancer.
- Trial name
- NCT02954536
- Testing
- pembrolizumab, trastuzumab, capecitabine
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glycemic Control
Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy of 2 doses of TAK-875 (25 mg and 50 mg), once daily (QD), plus metformin compared to placebo plus metformin and sitagliptin plus metformin on lowering blood sugar.
- Trial name
- NCT01549964
- Testing
- Fasiglifam (TAK-875), Sitagliptin
- Where
- 160 sites in United States, Australia and 9 more
- Volunteers
- 916 people
- Sponsor
- Takeda
Acute Myeloid Leukemia, Down Syndrome
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome.
- Conditions
- Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome
- Trial name
- NCT02521493
- Testing
- Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine
- Where
- 191 sites in United States, Australia and 4 more
- Volunteers
- 280 people
- Sponsor
- Children's Oncology Group
Essential Hypertension
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil plus chlorthalidone, once daily (QD), to olmesartan medoxomil plus hydrochlorothiazide in participants with moderate to severe…
- Trial name
- NCT01033071
- Testing
- Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide
- Where
- 94 sites in United States, Canada
- Volunteers
- 1,071 people
- Sponsor
- Takeda
Breast Cancer
Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer
The primary purpose of this study is to help answer the following research questions: whether the chemotherapy combination therapy Pemetrexed-Carboplatin or Gemcitabine-Vinorelbine can help participants with advanced breast…
- Trial name
- NCT00325234
- Testing
- Pemetrexed, Carboplatin, Gemcitabine
- Where
- 22 sites in Germany, Italy and 3 more
- Volunteers
- 135 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
This is a multi-centre, phase II, open-label, two-stage design, single-arm study in patients with hormone-refractory prostate cancer (HRPC) with advanced (rising PSA) and/or metastatic disease and who have had prior anti-androgen…
- Trial name
- NCT00278993
- Testing
- E7389
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- Eisai Inc.
Breast Cancer
Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy
This is a diagnostic accuracy study to evaluate if two novel ultrasound (US) techniques, quantitative 3D subharmonic imaging (SHI) and Subharmonic Aided Pressure Estimation (SHAPE), used with an intravenous ultrasound contrast…
- Trial name
- NCT02115607
- Testing
- Definity infusion
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Rectal Cancer
Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer
The purpose of this study is to evaluate the disease-free survival in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy with fluoropyrimidines and surgery followed by adjuvant combination…
- Trial name
- NCT00807911
- Testing
- Adjuvant FL, Adjuvant FOLFOX
- Where
- 6 sites in South Korea
- Volunteers
- 322 people
- Sponsor
- Asan Medical Center
Gastric Cancer, Gastroesophageal Junction Cancer
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- CheckMate649 (NCT02872116)
- Testing
- Nivolumab, Ipilimumab, Oxaliplatin
- Where
- 179 sites in United States, Argentina and 27 more
- Volunteers
- 2,031 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer
Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- PIMABI (NCT00655499)
- Testing
- Panitumumab, Irinotecan hydrochloride, Chromogenic in situ hybridization
- Where
- 9 sites in France
- Volunteers
- 65 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Adrenal Cortex Neoplasms
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
This study will examine the safety and effectiveness of treating adrenocortical cancer with combination chemotherapy using doxorubicin, vincristine, and etoposide in addition to the drugs mitotane and tariquidar and, when…
- Trial name
- NCT00071058
- Testing
- XR9576 (Tariquidar)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Dysphagia, Head and Neck Cancer
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
- Trial name
- NCT00503776
- Testing
- exercise intervention, amifostine trihydrate, therapeutic dietary intervention
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Prostate Cancer
Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
The purpose of this study is to determine if continued treatment with Enzalutamide is effective in patients with metastatic prostate cancer.
- Trial name
- PLATO (NCT01995513)
- Testing
- Enzalutamide, Abiraterone, Prednisone
- Where
- 95 sites in United States, Australia and 9 more
- Volunteers
- 509 people
- Sponsor
- Pfizer
Prostate Cancer
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of adjuvant androgen deprivation and up to 6 cycles of…
- Trial name
- NCT03043807
- Testing
- Leuprolide Acetate, Docetaxel, Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy
The main aims of the study are: To check for side effects from TAK-994 and check what dose of TAK-994 participants can tolerate. To check what dose range provides adequate relief of narcolepsy symptoms.
- Trial name
- NCT04096560
- Testing
- TAK-994
- Where
- 78 sites in United States, Canada and 10 more
- Volunteers
- 97 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease, Erosive Esophagitis
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
The purpose of this study is to measure the in-vivo disintegration time of a single dexlansoprazole delayed-release orally disintegrating (OD) tablet.
- Conditions
- Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
- Trial name
- NCT02096458
- Testing
- Dexlansoprazole
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Takeda
Non-Squamous Non-Small Cell Lung Cancer
AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer
This open-label study will assess the efficacy and safety of Avastin with or without pemetrexed as maintenance therapy in patients with advanced, metastatic or recurrent non-small cell lung cancer.
- Trial name
- NCT00961415
- Testing
- bevacizumab [Avastin], cisplatin, pemetrexed
- Where
- 91 sites in France, Germany and 10 more
- Volunteers
- 376 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
The purpose of this study is to test the safety and effectiveness of erlotinib and FOLFOX in patients with esophageal or gastro-esophageal cancer that cannot be removed by surgery.
- Trial name
- NCT00539617
- Testing
- Erlotinib, 5-fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Triple Negative Breast Cancer (TNBC)
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
The study will consist of two parts. In Part 1, the safety of pembrolizumab (MK-3475) in combination with one of three different chemotherapies will be assessed in the treatment of locally recurrent inoperable or metastatic…
- Trial name
- NCT02819518
- Testing
- Pembrolizumab, Nab-paclitaxel, Paclitaxel
- Volunteers
- 882 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.